Current Status and Unanswered Questions on the Use of Denosumab in Giant Cell Tumor of Bone

Overview

Journal Clin Sarcoma Res

Publisher Biomed Central

Date 2016 Sep 22

PMID 27651889

Citations 50

Authors

Czar Louie Gaston

Robert J Grimer

Michael Parry

Silvia Stacchiotti

Angelo Paolo Dei Tos

Hans Gelderblom

Stefano Ferrari

Giacomo G Baldi

Robin L Jones

Sant Chawla

Paolo Casali

Axel Lecesne

Jean-Yves Blay

Sander P D Dijkstra

David M Thomas

Piotr Rutkowski

Affiliations

Soon will be listed here.

Abstract

Denosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used pre-operatively to downstage tumours with large soft tissue extension to allow for less morbid surgery. The role of Denosumab for conventional limb GCT of bone is yet to be defined. Further studies are required to determine whether local recurrence rates will be decreased with the adjuvant use of Denosumab along with surgery. The long term use and toxicity of this agent is unknown as is the proportion of patients with primary or secondary resistance. It is advised that complicated cases of GCT requiring Denosumab treatment should be referred and followed up at expert centres. Collaborative studies involving further clinical trials and rigorous data collection are strongly recommended to identify the optimum use of this drug.

Citing Articles

A Case of Fibrosarcoma Arising in Giant Cell Tumor of Bone: a Rare Entity.

Singh A, Pujani M, Singh K, Yadav A, Prasad B, Agarwal P Indian J Surg Oncol. 2024; 15(Suppl 1):162-166.

PMID: 38545598 PMC: 10963346. DOI: 10.1007/s13193-023-01806-9.

Denosumab induction and Zoledronic acid maintenance therapy for recurrent unresectable giant cell tumour of the distal tibia: A case report with sustained tumour control after drug withdrawal.

Machak G, Bruland O, Romanova T, Kovalev A J Bone Oncol. 2024; 45:100596.

PMID: 38545297 PMC: 10966775. DOI: 10.1016/j.jbo.2024.100596.

Current indications for denosumab in benign bone tumours.

Imre A, Zoltan S, Miklos S EFORT Open Rev. 2023; 8(12):895-905.

PMID: 38038377 PMC: 10714381. DOI: 10.1530/EOR-23-0138.

Conversion in a Resectable Tumor after Denosumab Neoadjuvant in a Large Dorsal Giant Cells Tumor: A Case Report and a Literature Review.

Sereno M, Franco S, de la Reina L, Campo-Canaveral de la Cruz J, Munoz de Legaria M, Casado Saenz E Curr Oncol. 2023; 30(10):9335-9345.

PMID: 37887575 PMC: 10605573. DOI: 10.3390/curroncol30100675.

Endoscopic Endonasal Surgery for Uncommon Pathologies of the Sellar and Parasellar Regions.

Azab W, Khan T, Alqunaee M, Al Bader A, Yousef W Adv Tech Stand Neurosurg. 2023; 48:139-205.

PMID: 37770685 DOI: 10.1007/978-3-031-36785-4_7.

References

Kivioja A, Blomqvist C, Hietaniemi K, Trovik C, Walloe A, Bauer H . Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian Sarcoma Group study of 294 patients followed for a median time of 5 years. Acta Orthop. 2008; 79(1):86-93. DOI: 10.1080/17453670710014815. View

Behjati S, Tarpey P, Presneau N, Scheipl S, Pillay N, Van Loo P . Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013; 45(12):1479-82. PMC: 3839851. DOI: 10.1038/ng.2814. View

Gouin F, Rochwerger A, Di Marco A, Rosset P, Bonnevialle P, Fiorenza F . Adjuvant treatment with zoledronic acid after extensive curettage for giant cell tumours of bone. Eur J Cancer. 2014; 50(14):2425-31. DOI: 10.1016/j.ejca.2014.06.003. View

Mattei T, Ramos E, Rehman A, Shaw A, Patel S, Mendel E . Sustained long-term complete regression of a giant cell tumor of the spine after treatment with denosumab. Spine J. 2014; 14(7):e15-21. DOI: 10.1016/j.spinee.2014.02.019. View

Tse L, Wong K, Kumta S, Huang L, Chow T, Griffith J . Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study. Bone. 2007; 42(1):68-73. DOI: 10.1016/j.bone.2007.08.038. View

Huang L, Xu J, Wood D, Zheng M . Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol. 2000; 156(3):761-7. PMC: 1876848. DOI: 10.1016/s0002-9440(10)64942-5. View

Setsu N, Kobayashi E, Asano N, Yasui N, Kawamoto H, Kawai A . Severe hypercalcemia following denosumab treatment in a juvenile patient. J Bone Miner Metab. 2015; 34(1):118-22. DOI: 10.1007/s00774-015-0677-z. View

Gaston C, Bhumbra R, Watanuki M, Abudu A, Carter S, Jeys L . Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone?. J Bone Joint Surg Br. 2011; 93(12):1665-9. DOI: 10.1302/0301-620X.93B12.27663. View

Thangaraj R, Grimer R, Carter S, Stirling A, Spilsbury J, Spooner D . Giant cell tumour of the sacrum: a suggested algorithm for treatment. Eur Spine J. 2010; 19(7):1189-94. PMC: 2900020. DOI: 10.1007/s00586-009-1270-8. View

10.

Martin C, McCarthy E . Giant cell tumor of the sacrum and spine: series of 23 cases and a review of the literature. Iowa Orthop J. 2010; 30:69-75. PMC: 2958273. View

11.

Hakozaki M, Tajino T, Yamada H, Hasegawa O, Tasaki K, Watanabe K . Radiological and pathological characteristics of giant cell tumor of bone treated with denosumab. Diagn Pathol. 2014; 9:111. PMC: 4057823. DOI: 10.1186/1746-1596-9-111. View

12.

Kajizono M, Sada H, Sugiura Y, Soga Y, Kitamura Y, Matsuoka J . Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study. Biol Pharm Bull. 2015; 38(12):1850-5. DOI: 10.1248/bpb.b15-00385. View

13.

Gossai N, Hilgers M, Polgreen L, Greengard E . Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone. Pediatr Blood Cancer. 2015; 62(6):1078-80. DOI: 10.1002/pbc.25393. View

14.

Branstetter D, Nelson S, Manivel J, Blay J, Chawla S, Thomas D . Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012; 18(16):4415-24. DOI: 10.1158/1078-0432.CCR-12-0578. View

15.

Xu W, Li X, Huang W, Wang Y, Han S, Chen S . Factors affecting prognosis of patients with giant cell tumors of the mobile spine: retrospective analysis of 102 patients in a single center. Ann Surg Oncol. 2012; 20(3):804-10. DOI: 10.1245/s10434-012-2707-6. View

16.

Rutkowski P, Ferrari S, Grimer R, Stalley P, Dijkstra S, Pienkowski A . Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 2015; 22(9):2860-8. PMC: 4531146. DOI: 10.1245/s10434-015-4634-9. View

17.

Bussiere J, Pyrah I, Boyce R, Branstetter D, Loomis M, Andrews-Cleavenger D . Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol. 2013; 42:27-40. DOI: 10.1016/j.reprotox.2013.07.018. View

18.

Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G . Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008; 134(9):969-78. DOI: 10.1007/s00432-008-0370-x. View

19.

Girolami I, Mancini I, Simoni A, Baldi G, Simi L, Campanacci D . Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series. J Clin Pathol. 2015; 69(3):240-7. DOI: 10.1136/jclinpath-2015-203248. View

20.

Karras N, Polgreen L, Ogilvie C, Manivel J, Skubitz K, Lipsitz E . Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl. J Clin Oncol. 2013; 31(12):e200-2. PMC: 4878007. DOI: 10.1200/JCO.2012.46.4255. View